​

Tvardi Therapeutics (TVRD) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

TVRD Stock Forecast

Tvardi Therapeutics (TVRD) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a -19.14% decline from the last price of $3.71.

TVRD Stock Rating

Tvardi Therapeutics stock's rating consensus is Hold, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (25.00%), 2 Hold (50.00%), 1 Sell (25.00%), and 0 Strong Sell (0.00%).

Hold
Total 4 0 1 2 1 Strong Sell Sell Hold Buy Strong Buy

TVRD Price Target Upside V Benchmarks

TypeNameUpside
StockTvardi Therapeutics-19.14%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$3.00$30.20
Last Closing Price$3.71$3.71$3.71
Upside/Downside--19.14%714.02%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 26-43-18
Apr, 26-44--8
Mar, 26-44--8
Feb, 26-35--8
Jan, 26-35--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 20, 2026Barclays$3.00$3.39-11.50%-19.14%
Oct 13, 2025Barclays$5.00$6.69-25.26%34.77%
Oct 13, 2025Yasmeen RahimiPiper Sandler$4.00$6.54-38.84%7.82%
Oct 13, 2025Etzer DaroutBarclays$61.00$41.6046.63%1544.20%
Jun 12, 2025Yasmeen RahimiPiper Sandler$78.00$26.11198.74%2002.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 20, 2026BarclaysNegativeUnderweightdowngrade
Oct 14, 2025Raymond JamesOutperformMarket Performdowngrade
Oct 13, 2025BarclaysOverweightNegativedowngrade
Oct 13, 2025Cantor FitzgeraldOverweightNeutraldowngrade
Oct 13, 2025Piper SandlerOverweightNeutraldowngrade
Oct 13, 2025BarclaysOverweightinitialise
Jul 14, 2025Raymond JamesOutperforminitialise
Jul 11, 2025Cantor FitzgeraldOverweightinitialise
Jun 12, 2025Piper SandlerOverweightinitialise
May 21, 2025OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast$-3.16$-4.60-
High Forecast$-3.16$-4.60-
Low Forecast$-3.16$-4.60-
Surprise %---

Revenue Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Net Income Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast$-29.56M$-43.04M-
High Forecast$-29.56M$-43.04M-
Low Forecast$-29.56M$-43.04M-
Surprise %---

TVRD Forecast FAQ

Is Tvardi Therapeutics stock a buy?

Tvardi Therapeutics stock has a consensus rating of Hold, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Tvardi Therapeutics is a neutral investment for most analysts.

What is Tvardi Therapeutics's price target?

Tvardi Therapeutics's price target, set by 4 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential -19.14% change from the previous closing price of $3.71.

How does Tvardi Therapeutics stock forecast compare to its benchmarks?

Tvardi Therapeutics's stock forecast shows a -19.14% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tvardi Therapeutics over the past three months?

  • May 2026: 0% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.
  • April 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Tvardi Therapeutics’s EPS forecast?

Tvardi Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.16, marking a 0% decrease from the reported - in 2024. Estimates for the following years are $-4.6 in 2026, and $0 in 2027.

What is Tvardi Therapeutics’s revenue forecast?

Tvardi Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is Tvardi Therapeutics’s net income forecast?

Tvardi Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-29.564M, representing a 0% decrease from the reported - in 2024. Projections indicate $-43.035M in 2026, and $0 in 2027.